PlainRecalls
FDA Drug Moderate Class II Terminated

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

Reported: January 17, 2018 Initiated: December 4, 2017 #D-0154-2018

Product Description

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

Reason for Recall

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Details

Recalling Firm
ALLERGAN
Units Affected
12,699 bottles
Distribution
U.S.A. nationwide
Location
Madison, NJ

Frequently Asked Questions

What product was recalled?
Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10. Recalled by ALLERGAN. Units affected: 12,699 bottles.
Why was this product recalled?
Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 17, 2018. Severity: Moderate. Recall number: D-0154-2018.